Arthur F. Ryan - Jan 2, 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
Director
Signature
/s/**Arthur F. Ryan
Stock symbol
REGN
Transactions as of
Jan 2, 2024
Transactions value $
-$89,990
Form type
4
Date filed
1/4/2024, 04:08 PM
Previous filing
Dec 4, 2023
Next filing
Feb 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Sale -$874 -1 -0.01% $873.91 18.4K Jan 2, 2024 Direct F1
transaction REGN Common Stock Sale -$1.77K -2 -0.01% $886.26 18.4K Jan 2, 2024 Direct F1
transaction REGN Common Stock Sale -$887 -1 -0.01% $887.13 18.4K Jan 2, 2024 Direct F1
transaction REGN Common Stock Sale -$892 -1 -0.01% $892.00 18.4K Jan 2, 2024 Direct F1
transaction REGN Common Stock Sale -$7.17K -8 -0.04% $896.47 18.4K Jan 2, 2024 Direct F1, F2
transaction REGN Common Stock Sale -$2.69K -3 -0.02% $897.41 18.4K Jan 2, 2024 Direct F1, F3
transaction REGN Common Stock Sale -$5.39K -6 -0.03% $898.76 18.4K Jan 2, 2024 Direct F1, F4
transaction REGN Common Stock Sale -$12.6K -14 -0.08% $899.66 18.4K Jan 2, 2024 Direct F1, F5
transaction REGN Common Stock Sale -$26.1K -29 -0.16% $900.59 18.4K Jan 2, 2024 Direct F1, F6
transaction REGN Common Stock Sale -$8.11K -9 -0.05% $901.46 18.4K Jan 2, 2024 Direct F1, F7
transaction REGN Common Stock Sale -$9.02K -10 -0.05% $902.37 18.4K Jan 2, 2024 Direct F1, F8
transaction REGN Common Stock Sale -$11.7K -13 -0.07% $903.49 18.4K Jan 2, 2024 Direct F1, F9
transaction REGN Common Stock Sale -$2.71K -3 -0.02% $904.49 18.3K Jan 2, 2024 Direct F1, F10
transaction REGN Common Stock Award $0 +135 +0.74% $0.00 18.5K Jan 2, 2024 Direct F11

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Award $0 +1.61K $0.00 1.61K Jan 2, 2024 Common Stock 1.61K $888.34 Direct F12
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023.
F2 Represents volume-weighted average price of sales of 8 shares of Company stock on January 2, 2024 at prices ranging from $896.21 to $896.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price.
F3 Represents volume-weighted average price of sales of 3 shares of Company stock on January 2, 2024 at prices ranging from $897.35 to $897.54. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price.
F4 Represents volume-weighted average price of sales of 6 shares of Company stock on January 2, 2024 at prices ranging from $898.45 to $898.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price.
F5 Represents volume-weighted average price of sales of 14 shares of Company stock on January 2, 2024 at prices ranging from $899.08 to $899.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price.
F6 Represents volume-weighted average price of sales of 29 shares of Company stock on January 2, 2024 at prices ranging from $900.00 to $900.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price.
F7 Represents volume-weighted average price of sales of 9 shares of Company stock on January 2, 2024 at prices ranging from $901.03 to $901.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price.
F8 Represents volume-weighted average price of sales of 10 shares of Company stock on January 2, 2024 at prices ranging from $902.14 to $902.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price.
F9 Represents volume-weighted average price of sales of 13 shares of Company stock on January 2, 2024 at prices ranging from $903.13 to $903.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price.
F10 Represents volume-weighted average price of sales of 3 shares of Company stock on January 2, 2024 at prices ranging from $904.00 to $904.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price.
F11 Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Company's common stock.
F12 On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.